ESC Congress Recap: High-Impact Clinical Trials, with Deepak Bhatt, MD, MPH, MBA
ESC Congress 2024 featured 4,400 abstracts, including 112 studies published simultaneously. Deepak Bhatt highlighted FINEARTS-HF, ABYSS, RESHAPE-HF2, and SHAM-PVI. FINEARTS-HF showed finerenone reduced heart failure events by 16%. ABYSS found no benefit in stopping beta-blockers post-MI. RESHAPE-HF2 supported MitraClip use in heart failure with mitral regurgitation. SHAM-PVI found pulmonary vein isolation more effective than a sham procedure for atrial fibrillation.
Reference News
ESC Congress 2024 featured 4,400 abstracts, including 112 studies published simultaneously. Deepak Bhatt highlighted FINEARTS-HF, ABYSS, RESHAPE-HF2, and SHAM-PVI. FINEARTS-HF showed finerenone reduced heart failure events by 16%. ABYSS found no benefit in stopping beta-blockers post-MI. RESHAPE-HF2 supported MitraClip use in heart failure with mitral regurgitation. SHAM-PVI found pulmonary vein isolation more effective than a sham procedure for atrial fibrillation.
The 2024 ESC Congress in London featured new clinical guidelines and late-breaking trials, emphasizing personalized care and international collaboration. Highlights included updated guidelines for atrial fibrillation, hypertension, peripheral artery disease, and chronic coronary syndromes, and notable trials like FINEARTS-HF, which demonstrated finerenone's benefits in heart failure treatment. The Congress also highlighted the need for improved cardiovascular risk assessment methods.